Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
boston blog main
3
×
boston top stories
clinical trials
life sciences
national blog main
fda
national top stories
new york blog main
new york top stories
paul matteis
abbvie
acorda therapeutics
acute hepatic porphyrias
akin akinc
alder biopharmaceuticals
alnylam pharmaceuticals
amgen
aminolevulinic acid
ampyra
apokyn
apomorphine
biotech
boston
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
dalfampridine
david rind
detroit blog main
detroit top stories
drugs
duopa
eli lilly
episodic migraine
eptinezumab
erenumab
food and drug administration
fremanezumab
galcanezumab
What
drug
3
×
fda
3
×
nod
3
×
approval
gets
new
acorda
ago
alnylam
amgen
approved
candidates
class
cope
developed
disease
episodes
friday
head
help
indicated
interference
late
looms
meant
medications
medicine
medicines
migraine
pain
parkinson’s
patients
pharmaceuticals
preventive
quick
rival
rna
rnai
second
seek
Language
Current search:
photo
×
fda
×
" boston blog main "
×
drug
×
nod
×
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines